The blocking of S100A12 from binding to TLR4 may inhibit the downstream pro-inflammatory signal and is therefore of potential value for designing effective therapeutics against COVID-19-associated acute necrotizing encephalopathy. This evidence concerns the gene TLR4 and COVID-19.